1. Most Promising Therapies in Interventional Cardiology
- Author
-
Megan K. Yee, M Khurram Afzal, Anmol Pitliya, Sargun S Walia, Sudarshana Datta, Fahad Al Khalfan, Mathieu Kerneis, Tarek Nafee, Iqra Qamar, C. Michael Gibson, Hassan A Kazmi, Arzu Kalayci, Mehrian Jafarizade, Michel Zeitouni, Beth Israel Deaconess Medical Center [Boston] (BIDMC), Harvard Medical School [Boston] (HMS), Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], and Sorbonne Université (SU)
- Subjects
Acute coronary syndrome ,medicine.medical_specialty ,Cardiac Catheterization ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Cardiology ,030204 cardiovascular system & hematology ,Coronary artery disease ,Percutaneous coronary intervention ,03 medical and health sciences ,0302 clinical medicine ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Implantable device ,medicine ,Risk of mortality ,Humans ,030212 general & internal medicine ,Myocardial infarction ,Registries ,Risk factor ,Intensive care medicine ,Interventional cardiology ,business.industry ,Stent ,medicine.disease ,3. Good health ,Cardiology and Cardiovascular Medicine ,business - Abstract
International audience; PURPOSE OF REVIEW:The last 40 years of clinical research in interventional cardiology were extraordinarily innovative. This article will review the most promising up and coming interventional cardiovascular therapies, with a primary focus on the treatment of coronary artery disease.RECENT FINDINGS:From the first stent, to the first transcatheter aortic valve implantation (TAVI), and the left appendage closure technique, percutaneous interventions revolutionized the treatment of multiple diseases and dramatically improved the prognosis of many patients. While these advances have decreased the risk of mortality in some patients (such as ST-elevation myocardial infarction), 15% of acute coronary syndrome (ACS) patients still experience recurrent ischemic events within the first year, challenging us to develop new pharmaceutical targets and new devices. The continued emergence of data supporting inflammation as a risk factor and pharmacologic target as well as data supporting the importance of cholesterol efflux have identified novel therapeutic targets that may play a major role in the improvement of prognosis of patients with coronary artery disease. In addition, novel medical devices are being developed to allow even earlier detection of acute cardiac events and to support high-risk percutaneous coronary interventions. Advances in computing and the ability to analyze large datasets will allow us to use artificial intelligence to augment the clinician patient experience, both in and out of the catheterization laboratory, with live procedural guidance as well as pre- and post-operative prognostication tools.
- Published
- 2019